- Home
- EML vs CRGX Comparison
EML vs CRGX Comparison
Compare EML & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- CRGX
- Stock Information
- Founded
- EML 1858
- CRGX 2021
- Country
- EML United States
- CRGX United States
- Employees
- EML N/A
- CRGX N/A
- Industry
- EML Industrial Machinery/Components
- CRGX
- Sector
- EML Consumer Discretionary
- CRGX
- Exchange
- EML Nasdaq
- CRGX Nasdaq
- Market Cap
- EML 161.7M
- CRGX 180.4M
- IPO Year
- EML N/A
- CRGX 2023
- Fundamental
- Price
- EML $23.74
- CRGX $4.03
- Analyst Decision
- EML
- CRGX Hold
- Analyst Count
- EML 0
- CRGX 7
- Target Price
- EML N/A
- CRGX $4.67
- AVG Volume (30 Days)
- EML 7.0K
- CRGX 783.4K
- Earning Date
- EML 05-05-2025
- CRGX 05-13-2025
- Dividend Yield
- EML 1.86%
- CRGX N/A
- EPS Growth
- EML N/A
- CRGX N/A
- EPS
- EML N/A
- CRGX N/A
- Revenue
- EML $272,751,967.00
- CRGX N/A
- Revenue This Year
- EML N/A
- CRGX $64.32
- Revenue Next Year
- EML N/A
- CRGX N/A
- P/E Ratio
- EML $11.13
- CRGX N/A
- Revenue Growth
- EML 5.37
- CRGX N/A
- 52 Week Low
- EML $23.15
- CRGX $3.00
- 52 Week High
- EML $35.03
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- EML 33.66
- CRGX 33.79
- Support Level
- EML $25.26
- CRGX $3.99
- Resistance Level
- EML $25.71
- CRGX $4.25
- Average True Range (ATR)
- EML 0.54
- CRGX 0.20
- MACD
- EML -0.22
- CRGX 0.07
- Stochastic Oscillator
- EML 0.00
- CRGX 6.38
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.